Article Information
History
- October 6, 2021.
Article Versions
- Version 1 (October 5, 2021 - 07:25).
- Version 2 (October 5, 2021 - 15:07).
- You are currently viewing Version 3 of this article (October 6, 2021 - 08:31).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Simon Jochum*,1,
- Imke Kirste2,
- Sayuri Hortsch1,
- Veit Peter Grunert1,
- Holly Legault3,
- Udo Eichenlaub1,
- Basel Kashlan4 and
- Rolando Pajon*,3
- 1Roche Diagnostics GmbH, Penzberg, Germany
- 2Roche Diagnostics Operations, Indianapolis, USA
- 3Moderna, Cambridge, MA, USA
- 4PPD Inc., Wilmington, NC, USA
- ↵*Joint corresponding authors. Correspondence:
Simon Jochum, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany, Tel: +49 8856 60 10562, Email: simon.jochum{at}roche.com, Rolando Pajon, Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA, Tel: +1 (617) 803-6627, Email: rolando.pajon{at}modernatx.com
Posted October 06, 2021.
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial
